Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Journal of the National Cancer Institute|April 30, 2009
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapyF P O'Malley, S Chia, D Tu, et al.
Breast Cancer Research and Treatment|April 27, 2011
Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trialF P O'Malley, S Chia, D Tu, et al.
The New England Journal of Medicine|October 13, 2001
A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patientsD J Sargent, R M Goldberg, S D Jacobson, et al.
European Journal of Cancer (Oxford, England : 1990)|December 24, 2017
Outcomes in women with invasive ductal or invasive lobular early stage breast cancer treated with anastrozole or exemestane in CCTG (NCIC CTG) MA.27K Strasser-Weippl, G Sudan, R Ramjeesingh, et al.
Breast Cancer Research and Treatment|September 17, 2020
Anthracycline-induced cardiotoxicity in patients with early-stage breast cancer: the Canadian Cancer Trials Group (CCTG) MA.21 experienceS F Dent, J Botros, M Rushton, et al.
The New England Journal of Medicine|December 9, 1993
Escalated as compared with standard doses of doxorubicin in BACOP therapy for patients with non-Hodgkin's lymphomaR M Meyer, I C Quirt, J R Skillings, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 12, 2007
Patterns of disease progression and outcomes in a randomized trial testing ABVD alone for patients with limited-stage Hodgkin lymphomaD A Macdonald, K Ding, M K Gospodarowicz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 21, 2016
Treatment outcomes for older patients with relapsed/refractory aggressive lymphoma receiving salvage chemotherapy and autologous stem cell transplantation are similar to younger patients: a subgroup analysis from the phase III CCTG LY.12 trialK Davison, B E Chen, V Kukreti, et al.
British Journal of Cancer|August 19, 2015
TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trialJ M S Bartlett, T O Nielsen, D Gao, et al.
Breast Cancer Research and Treatment|October 12, 2013
Do alternative methods of measuring tumor size, including consideration of multicentric/multifocal disease, enhance prognostic information beyond TNM staging in women with early stage breast cancer: an analysis of the NCIC CTG MA.5 and MA.12 clinical trialsJ F Hilton, N Bouganim, B Dong, et al.
Pageof 3